{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:44:32Z","timestamp":1791045872821,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020552","name":"Ministry of Higher Education, Research and Innovation","doi-asserted-by":"publisher","award":["D.P.S \/3666\/2017"],"award-info":[{"award-number":["D.P.S \/3666\/2017"]}],"id":[{"id":"10.13039\/100020552","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Radioiodine (\n                      <jats:sup>131<\/jats:sup>\n                      I) dosimetry is used to maximise tumour dose while reducing the chances of toxicity. High thyroid-stimulating-hormone (TSH) levels are required for\n                      <jats:sup>131<\/jats:sup>\n                      I treatment, achieved through hormone withdrawal or intramuscular injection of recombinant human TSH (rhTSH). Both approaches have shown equivalent results, with the rhTSH approach reported to reduce morbidity and avoid hypothyroidism. There are established differences in\n                      <jats:sup>131<\/jats:sup>\n                      I biokinetics using each method\n                      <jats:italic>.<\/jats:italic>\n                      This clinical cohort study investigated if pretherapy iodine biokinetics as measured using a dosimetry protocol without a dose of rhTSH are predictive of post therapy biokinetics in patients prepared with rhTSH injection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirteen patients with differentiated thyroid cancer (DTC) were recruited. An adaptation of the European Association of Nuclear Medicine (EANM) dosimetry protocol was conducted at St James\u2019s Hospital, Ireland. The maximum tolerable activity (MTA) was calculated using the EANM, Association of Physics in Medicine (AIFM) and Traino models, after administering\n                      <jats:sup>131<\/jats:sup>\n                      I, and subsequent whole-body (WB) dose-rate measurements and blood-sampling were carried out. The MTA estimated from pre-therapeutic (PT)\n                      <jats:sup>131<\/jats:sup>\n                      I tracer administration (6.07\u2009\u00b1\u20092.46 MBq) was compared to during therapy (DT) administration (3.88\u2009\u00b1\u20090.16 GBq).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The PT WB residence-time overestimated the DT with a difference of \u2212\u20097.72\u2009\u00b1\u20098.13% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), while no significant difference is reported between the blood residence-time (1.13\u2009\u00b1\u20096.49%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.559). The EANM model reported the lowest difference of 1.73\u2009\u00b1\u20094.83% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.241) in MTA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study validated the feasibility of using dosimetry in euthyroid patients to predict therapeutic\n                      <jats:sup>131<\/jats:sup>\n                      I biokinetics in DTC patients prepared with rhTSH.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-025-02042-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:33:17Z","timestamp":1743888797000},"page":"676-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8885-2856","authenticated-orcid":false,"given":"Amna Juma","family":"Al Jabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"Cournane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"1","key":"2042_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40658-017-0194-3","volume":"4","author":"C Stokke","year":"2017","unstructured":"Stokke C, Gabi\u00f1a PM, Soln\u00fd P, Cicone F, Sandstr\u00f6m M, Gleisner KS, et al. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Phys. 2017;4(1):1\u20139","journal-title":"EJNMMI Phys"},{"key":"2042_CR2","unstructured":"Directive C. 59\/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89\/618\/Euratom, 90\/641\/Euratom, 96\/29\/Euratom, 97\/43\/Euratom and 2003\/122\/Euratom. Euratom; 2013."},{"issue":"5","key":"2042_CR3","first-page":"546","volume":"53","author":"C Chiesa","year":"2009","unstructured":"Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53(5):546\u201361.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"Supplement 2","key":"2042_CR4","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","volume":"58","author":"U Eberlein","year":"2017","unstructured":"Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58(Supplement 2):97S-103S.","journal-title":"J Nucl Med"},{"key":"2042_CR5","first-page":"1317","volume":"2","author":"RS Benua","year":"1986","unstructured":"Benua RS. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Front Thyroidol. 1986; 2:1317\u20131321.","journal-title":"Front Thyroidol"},{"issue":"7","key":"2042_CR6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","volume":"35","author":"M Lassmann","year":"2008","unstructured":"Lassmann M, H\u00e4nscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2042_CR7","first-page":"171","volume":"87","author":"RS Benua","year":"1962","unstructured":"Benua RS, Cicale NR, Sonenberg M, Rawson R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171\u201382.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"issue":"5","key":"2042_CR8","first-page":"899","volume":"46","author":"G Sgouros","year":"2005","unstructured":"Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. J Nucl Med. 2005;46(5):899\u2013900.","journal-title":"J Nucl Med"},{"issue":"5","key":"2042_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s00259-009-1303-x","volume":"37","author":"FA Verburg","year":"2010","unstructured":"Verburg FA, H\u00e4nscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, et al. Dosimetry-guided high-activity 131 I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37(5):896\u2013903.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2042_CR10","doi-asserted-by":"publisher","first-page":"E1268","DOI":"10.1210\/jc.2011-0520","volume":"96","author":"FA Verburg","year":"2011","unstructured":"Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees SA, et al. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(8):E1268\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2042_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"issue":"7","key":"2042_CR12","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1210\/jc.2009-2528","volume":"95","author":"D Ta\u00efeb","year":"2010","unstructured":"Ta\u00efeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2010;95(7):3283\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2042_CR13","first-page":"648","volume":"47","author":"H H\u00e4nscheid","year":"2006","unstructured":"H\u00e4nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648\u201354.","journal-title":"J Nucl Med"},{"issue":"10","key":"2042_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-003-1230-1","volume":"30","author":"M Luster","year":"2003","unstructured":"Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, H\u00e4nscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30(10):1371\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2042_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00259-008-0754-9","volume":"35","author":"I Borget","year":"2008","unstructured":"Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging. 2008;35:1457\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2042_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s00259-013-2387-x","volume":"40","author":"H H\u00e4nscheid","year":"2013","unstructured":"H\u00e4nscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40(7):1126\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2042_CR17","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1088\/0031-9155\/61\/11\/4316","volume":"61","author":"A Giostra","year":"2016","unstructured":"Giostra A, Richetta E, Pasquino M, Miranti A, Cutaia C, Brusasco G, et al. Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results. Phys Med Biol. 2016;61(11):4316\u20134326.","journal-title":"Phys Med Biol"},{"issue":"6","key":"2042_CR18","first-page":"515","volume":"56","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, et al. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high131I activity: the experience of Busto Arsizio Hospital (Italy). Q J Nucl Med Mol Imaging. 2012;56(6):515\u201321.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"3","key":"2042_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","volume":"85","author":"MG Stabin","year":"2003","unstructured":"Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85(3):294\u2013310.","journal-title":"Health Phys"},{"issue":"17","key":"2042_CR20","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1088\/0031-9155\/52\/17\/009","volume":"52","author":"A Traino","year":"2007","unstructured":"Traino A, Ferrari M, Cremonesi M, Stabin M. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52(17):5231.","journal-title":"Phys Med Biol"},{"issue":"7","key":"2042_CR21","first-page":"1114","volume":"49","author":"P Zanzonico","year":"2008","unstructured":"Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med Off Publ Soc Nucl Med. 2008;49(7):1114.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"3","key":"2042_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med"},{"issue":"5","key":"2042_CR23","first-page":"830","volume":"32","author":"G Akabani","year":"1991","unstructured":"Akabani G, Poston JW. Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med. 1991;32(5):830\u20134.","journal-title":"J Nucl Med"},{"key":"2042_CR24","unstructured":"Bevington P. Data reduction and error analysis. (No Title). 2003."},{"key":"2042_CR25","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","volume":"45","author":"JI Gear","year":"2018","unstructured":"Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45:2456\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2042_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/ed075p119","volume":"75","author":"DC Harris","year":"1998","unstructured":"Harris DC. Nonlinear least-squares curve fitting with Microsoft Excel Solver. J Chem Educ. 1998;75(1):119.","journal-title":"J Chem Educ"},{"issue":"21","key":"2042_CR27","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1001\/jama.1990.03450210108045","volume":"264","author":"VL Clark","year":"1990","unstructured":"Clark VL, Kruse JA. Clinical methods: the history, physical, and laboratory examinations. JAMA. 1990;264(21):2808\u20139.","journal-title":"JAMA"},{"issue":"6","key":"2042_CR28","first-page":"515","volume":"56","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, et al. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). Quart J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med (AIMN) Int Assoc Radiopharmacol (IAR) Sect Soc. 2012;56(6):515\u201321.","journal-title":"Quart J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med (AIMN) Int Assoc Radiopharmacol (IAR) Sect Soc."},{"issue":"3","key":"2042_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1088\/0031-9155\/60\/3\/1141","volume":"60","author":"A Miranti","year":"2015","unstructured":"Miranti A, Giostra A, Richetta E, Gino E, Pellerito RE, Stasi M. Comparison of mathematical models for red marrow and blood absorbed dose estimation in the radioiodine treatment of advanced differentiated thyroid carcinoma. Phys Med Biol. 2015;60(3):1141\u201357.","journal-title":"Phys Med Biol"},{"issue":"3","key":"2042_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MNM.0000000000000439","volume":"37","author":"N Yeyin","year":"2016","unstructured":"Yeyin N, Cavdar I, Uslu L, Abuqbeitah M, Demir M. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure. Nucl Med Commun. 2016;37(3):283\u20137.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2042_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.14310\/horm.2002.11193","volume":"5","author":"C Alevizaki","year":"2006","unstructured":"Alevizaki C, Molfetas M, Samartzis A, Vlassopoulou B, Vassilopoulos C, Rondogianni P, et al. Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. HORMONES-ATHENS. 2006;5(4):276.","journal-title":"HORMONES-ATHENS"},{"issue":"4","key":"2042_CR32","first-page":"619","volume":"45","author":"M Lassmann","year":"2004","unstructured":"Lassmann M, Luster M, H\u00e4nscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45(4):619\u201325.","journal-title":"J Nucl Med"},{"issue":"2","key":"2042_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MNM.0b013e3283169148","volume":"30","author":"SR Zakavi","year":"2009","unstructured":"Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30(2):169\u201375.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"2042_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00259-009-1315-6","volume":"37","author":"FA Verburg","year":"2010","unstructured":"Verburg FA, Stokkel MP, D\u00fcren C, Verkooijen RB, M\u00e4der U, van Isselt JW, et al. No survival difference after successful 131 I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):276\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2042_CR35","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2967\/jnumed.108.052464","volume":"49","author":"H Remy","year":"2008","unstructured":"Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med. 2008;49(9):1445\u201350.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02042-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:47:55Z","timestamp":1750146475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2042"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02042-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}